Spruce Biosciences (SPRB) Total Non-Current Liabilities (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Total Non-Current Liabilities of $17.6 million for Q1 2026, up 7.69% year-over-year from $16.3 million in Q1 2025, and up 67.35% quarter-over-quarter from $10.5 million in Q4 2025.
Spruce Biosciences (SPRB) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Total Non-Current Liabilities for 8 consecutive years, with $17.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 7.69% year-over-year to $17.6 million; the TTM figure through Mar 2026 stood at $17.6 million (up 7.69% YoY), while the FY2025 annual figure was $10.5 million, down 35.9% from the prior year.
- Total Non-Current Liabilities rose to $17.6 million in Q1 2026 per SPRB's latest filing, from $10.5 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $30.9 million in Q1 2023 and bottomed at $8.6 million in Q2 2025.
- Historically, Total Non-Current Liabilities has averaged $18.1 million across 5 years, with a median of $16.4 million in 2024.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities surged 111.17% — and 2024, when it slumped 51.83%.
- Spruce Biosciences' Total Non-Current Liabilities stood at $17.0 million in 2022, then soared by 60.0% to $27.2 million in 2023, then tumbled by 39.75% to $16.4 million in 2024, then sank by 35.9% to $10.5 million in 2025, then jumped by 67.35% to $17.6 million in 2026.
- Business Quant data shows SPRB's Total Non-Current Liabilities at $17.6 million in Q1 2026, $10.5 million in Q4 2025, and $9.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Spruce Biosciences | 127.07 Mn | 127.07 Mn | - | 15.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.80 Mn |
| Mar 31, 2026 | 17.58 Mn |
| Dec 31, 2025 | 10.51 Mn |
| Sep 30, 2025 | 9.93 Mn |
| Jun 30, 2025 | 8.64 Mn |
| Mar 31, 2025 | 16.33 Mn |
| Dec 31, 2024 | 16.39 Mn |
| Sep 30, 2024 | 13.19 Mn |
| Jun 30, 2024 | 16.09 Mn |
| Mar 31, 2024 | 20.67 Mn |
| Dec 31, 2023 | 27.20 Mn |
| Sep 30, 2023 | 27.38 Mn |
| Jun 30, 2023 | 29.20 Mn |
| Mar 31, 2023 | 30.94 Mn |
| Dec 31, 2022 | 17.00 Mn |
| Sep 30, 2022 | 16.68 Mn |
| Jun 30, 2022 | 15.28 Mn |
| Mar 31, 2022 | 14.65 Mn |
| Dec 31, 2021 | 15.04 Mn |
| Sep 30, 2021 | 15.32 Mn |